970 related articles for article (PubMed ID: 27248342)
1. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
2. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
3. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
4. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
5. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
6. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
7. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
[TBL] [Abstract][Full Text] [Related]
8. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
9. The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells.
Rosental B; Appel MY; Yossef R; Hadad U; Brusilovsky M; Porgador A
Curr Med Chem; 2012; 19(12):1780-91. PubMed ID: 22414084
[TBL] [Abstract][Full Text] [Related]
10. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
12. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
13. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
14. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
15. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
16. Targeting NK-cell checkpoints for cancer immunotherapy.
Muntasell A; Ochoa MC; Cordeiro L; Berraondo P; López-Díaz de Cerio A; Cabo M; López-Botet M; Melero I
Curr Opin Immunol; 2017 Apr; 45():73-81. PubMed ID: 28236750
[TBL] [Abstract][Full Text] [Related]
17. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
20. Recognition of tumor cells by the innate immune system.
Soloski MJ
Curr Opin Immunol; 2001 Apr; 13(2):154-62. PubMed ID: 11228407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]